Merck to buy Acceleron for about $11.5 billion in rare disease drugs push

imageStock Markets18 minutes ago (Sep 30, 2021 07:05AM ET)

(C) Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo


(Reuters) – Merck & Co will buy drugmaker Acceleron Pharma (NASDAQ:XLRN) Inc for about $11.5 billion, the companies said on Thursday, as the U.S. pharmaceutical giant looks to beef up its portfolio with drugs for rare diseases.

Merck will pay $180 per Acceleron share in cash, representing a premium of about 2.6% to the stock’s closing price on Wednesday, according to Refinitiv data.

Cambridge, Massachusetts-based Acceleron focuses on the discovery, development and commercialization of therapeutics to treat cardiovascular and other blood-related disorders.

The company is developing Sotatercept, which is currently in a late-stage study, to treat a rare cardiovascular disease called pulmonary arterial hypertension (PAH), a type of high blood pressure that affects the lungs.

Rare disease treatments is a lucrative market for drugmakers as they can charge more for these unique drugs. The PAH market is expected to grow at a 5% compound annual growth rate from 2019 to 2029 in the seven major markets, according to GlobalData, a data and analytics company.

In 2017, Johnson & Johnson (NYSE:JNJ) bought Swiss biotech company Actelion and its pulmonary hypertension drugs in a $30 billion all-cash deal. Merck is also developing a treatment for the indication, which is currently in a mid-stage study. Along with Sotatercept, Merck will gain access to Reblozyl, which is approved for the treatment of two blood-related disorders, including anemia in patients with beta thalassemia.

The transaction is expected to close in the fourth quarter.

Merck to buy Acceleron for about $11.5 billion in rare disease drugs push

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles

Dollar Down, Steadies as Investors Gauge Interest Rate Hike Pace

Forex31 minutes ago (Oct 24, 2021 10:51PM ET) (C) Reuters. By Gina Lee - The dollar was down on Monday morning in Asia, steadying after...

Former Saudi spymaster calls on Biden administration for help on his jailed kids

World57 minutes ago (Oct 24, 2021 10:26PM ET) 3/3 (C) Reuters. Former Saudi intelligence official Saad al-Jabri (R) poses with his son Omar al-Jabri whilst visiting...

Evergrande, EV unit shares jump after chairman signals business shift

Stock Markets8 minutes ago (Oct 24, 2021 10:16PM ET) 2/2 (C) Reuters. FILE PHOTO: An aerial view shows residential buildings at the construction site of Evergrande...

Latest Posts

Stay in touch

Join the exclusive subscription today and get premium articles for free